ALDEYRA THERAPEUTICS, INC.: 10-Q filed 2015-11-13

Name: ALDEYRA THERAPEUTICS, INC.: 10-Q filed 2015-11-13
Creator: ALDEYRA THERAPEUTICS, INC.

What ALDEYRA THERAPEUTICS, INC. reported in its quarterly report filed 2015-11-13 (fiscal Q3 2015): 29 published measures, 81 facts as tagged in accession 0001193125-15-376648.

This filing

Form: 10-Q (quarterly report)
Filed: 2015-11-13
Fiscal period: fiscal Q3 2015
Accession: 0001193125-15-376648 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ALDEYRA THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2015-09-30	31,350,399	USD
At 2014-12-31	8,787,103	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2015-09-30	2,655,036	USD
At 2014-12-31	2,503,045	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2015-09-30	28,695,363	USD
At 2014-12-31	6,284,058	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2015-09-30	30,618,365	USD
At 2014-12-31	8,527,304	USD
At 2014-09-30	10,142,137	USD
At 2013-12-31	3,262,354	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-3,365,687	USD	92
2015-01-01 to 2015-09-30	-7,734,431	USD	273
2014-07-01 to 2014-09-30	-2,009,206	USD	92
2014-01-01 to 2014-09-30	-2,742,580	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	86,119	USD	273
2014-01-01 to 2014-09-30	6,107	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2015-09-30	-54,246,028	USD
At 2014-12-31	-46,511,597	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	9,712,521	shares	92
2015-01-01 to 2015-09-30	8,270,405	shares	273
2014-07-01 to 2014-09-30	5,565,415	shares	92
2014-01-01 to 2014-09-30	3,229,338	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	9,712,521	shares	92
2015-01-01 to 2015-09-30	8,270,405	shares	273
2014-07-01 to 2014-09-30	5,565,415	shares	92
2014-01-01 to 2014-09-30	3,272,730	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-0.35	USD/shares	92
2015-01-01 to 2015-09-30	-0.94	USD/shares	273
2014-07-01 to 2014-09-30	-0.36	USD/shares	92
2014-01-01 to 2014-09-30	-2.21	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-0.35	USD/shares	92
2015-01-01 to 2015-09-30	-0.94	USD/shares	273
2014-07-01 to 2014-09-30	-0.36	USD/shares	92
2014-01-01 to 2014-09-30	-2.89	USD/shares	273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	0	USD	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2015-09-30	88,463	USD
At 2014-12-31	12,993	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	1,639,930	USD	273
2014-01-01 to 2014-09-30	1,571,895	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-3,337,606	USD	92
2015-01-01 to 2015-09-30	-7,650,117	USD	273
2014-07-01 to 2014-09-30	-1,968,135	USD	92
2014-01-01 to 2014-09-30	-4,859,546	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2015-09-30	31,225,700	USD
At 2014-12-31	8,759,872	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	28,081	USD	92
2015-01-01 to 2015-09-30	84,314	USD	273
2014-07-01 to 2014-09-30	41,071	USD	92
2014-01-01 to 2014-09-30	210,539	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2015-09-30	1,373,948	USD
At 2014-12-31	1,327,564	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2015-09-30	743,623	USD
At 2014-12-31	341,294	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	2,076,410	USD	92
2015-01-01 to 2015-09-30	4,461,941	USD	273
2014-07-01 to 2014-09-30	1,195,668	USD	92
2014-01-01 to 2014-09-30	2,303,854	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2015-09-30	9,712,521	shares
At 2014-12-31	5,565,415	shares

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2015-09-30	630,325	USD
At 2014-12-31	908,724	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2015-09-30	607,335	USD
At 2014-12-31	232,568	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-3,365,687	USD	92
2015-01-01 to 2015-09-30	-7,734,431	USD	273
2014-07-01 to 2014-09-30	-2,009,206	USD	92
2014-01-01 to 2014-09-30	-7,129,232	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	1,261,196	USD	92
2015-01-01 to 2015-09-30	3,188,176	USD	273
2014-07-01 to 2014-09-30	772,467	USD	92
2014-01-01 to 2014-09-30	2,555,692	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	10,649	USD	273
2014-01-01 to 2014-09-30	339	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-28,081	USD	92
2015-01-01 to 2015-09-30	-84,314	USD	273
2014-07-01 to 2014-09-30	-41,071	USD	92
2014-01-01 to 2014-09-30	2,116,966	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	28,505,808	USD	273
2014-01-01 to 2014-09-30	10,055,005	USD	273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	402,329	USD	273
2014-01-01 to 2014-09-30	140,617	USD	273

Inspect the source

Entity: ALDEYRA THERAPEUTICS, INC. / CIK 0001341235
Captured: 2026-09-20T07:54:15.451Z
SEC response SHA-256: 71cda24b59474759e40949f545ab949ecdfc2871814e3cf45050931d1c516763

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001341235.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))